Associations Between Gestational Residential Radon Exposure and Term Low Birthweight in Connecticut, USA
Heo S, Li L, Son J, Koutrakis P, Bell M. Associations Between Gestational Residential Radon Exposure and Term Low Birthweight in Connecticut, USA. Epidemiology 2024, 35: 834-843. PMID: 39042464, PMCID: PMC11560713, DOI: 10.1097/ede.0000000000001771.Peer-Reviewed Original ResearchOdds ratioSingleton full-term birthsLow birth weight riskRadon exposureLow birthweightResidential radon exposureMaternal education levelLogistic regression modelsParticipant's addressFull-term birthImpaired fetal developmentInfant healthLow-incomeExposure to radonNational guidelinesExposure quartilesEducation levelGround-level exposuresExposure groupWeighted riskQuartile groupLow exposure groupReference groupFetal developmentGestational exposureImpact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
Petrylak D, Chia Y, Yu E, Powles T, Flaig T, Loriot Y, O'Donnell P, Heath E, Kojima T, Park S, Sonpavde G, Picus J, Matsubara N, Obara W, Chudasama V, Poondru S, Harrison M, Kim E, Brancato S, Rosenberg J. Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer. Journal Of Clinical Oncology 2024, 42: 4503-4503. DOI: 10.1200/jco.2024.42.16_suppl.4503.Peer-Reviewed Original ResearchMetastatic urothelial cancerEnfortumab vedotinDose modificationEV exposureUrothelial cancerPre-dose samplesAssociated with lower riskPopulation PK modelLikelihood of responseEV-201Median PFSOS benefitOS outcomesDose reductionExposure quartilesExposure-responsePK assessmentEfficacy outcomesSafety profilePeripheral neuropathySkin reactionsPK modelLow riskSafety outcomesDose response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply